Lexaria Bioscience Corp.

NasdaqCM:LEXX Stock Report

Market Cap: US$40.1m

Lexaria Bioscience Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:LEXX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Dec 24BuyUS$67,175Richard ChristopherIndividual27,172US$2.47
02 Dec 24BuyUS$51,217Richard ChristopherIndividual22,828US$2.24
31 Aug 24BuyUS$322,428Wayne BoosIndividual113,531US$2.84
31 Aug 24SellUS$1,691,293Wayne BoosIndividual533,531US$3.17
12 Aug 24BuyUS$5,008Catherine TurkelIndividual1,600US$3.13
31 Jul 24BuyUS$391,162Wayne BoosIndividual137,733US$2.84
31 Jul 24SellUS$10,268Vanessa CarleIndividual2,567US$4.00
31 Jul 24SellUS$751,155Wayne BoosIndividual242,308US$3.10
31 Mar 24BuyUS$1,707,881Wayne BoosIndividual563,657US$3.03
31 Mar 24SellUS$114,289Wayne BoosIndividual53,657US$2.13

Insider Trading Volume

Insider Buying: LEXX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LEXX?
Owner TypeNumber of SharesOwnership Percentage
Private Companies308,4871.77%
Institutions1,062,6646.09%
Individual Insiders1,441,0508.26%
Hedge Funds5,811,01933.3%
General Public8,829,37450.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.8%.

Top Shareholders

Top 25 shareholders own 49.21% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
33.3%
Armistice Capital LLC
5,811,019US$13.4m470%0.3%
3.44%
Wayne Boos
600,000US$1.4m-41.2%no data
2.73%
Invenomic Capital Management LP
475,773US$1.1m-7.36%0.09%
2.68%
Don Jackler
468,382US$1.1m0%no data
1.57%
Christopher Bunka
273,543US$629.1k0%no data
1.46%
CAB Financial Services Ltd.
254,412US$585.1k0%no data
0.86%
Geode Capital Management, LLC
150,391US$345.9k31%no data
0.62%
The Vanguard Group, Inc.
109,022US$250.8k16.5%no data
0.34%
GenTrust, LLC
60,000US$138.0k0%0.01%
0.31%
Docherty Management Ltd.
54,075US$124.4k0%no data
0.29%
Richard Christopher
50,000US$115.0k0%no data
0.26%
Raymond James Financial Services Advisors, Inc.
44,900US$103.3k-7.99%no data
0.23%
State Street Global Advisors, Inc.
39,301US$90.4k0%no data
0.16%
BlackRock, Inc.
27,445US$63.1k0%no data
0.14%
The Welch Group, LLC
24,000US$55.2k0%no data
0.13%
Morgan Stanley, Investment Banking and Brokerage Investments
22,982US$52.9k0%no data
0.11%
XTX Holdings Limited, Asset Management Arm
18,626US$42.8k47.8%no data
0.11%
Northern Trust Global Investments
18,389US$42.3k0%no data
0.08%
BMO Asset Management Corp.
14,000US$32.2k0%no data
0.079%
Wealth Enhancement Advisory Services, LLC
13,823US$31.8k0%no data
0.076%
William McKechnie
13,191US$30.3k0%no data
0.075%
HighTower Advisors, LLC
13,023US$30.0k0%no data
0.063%
Nicholas Baxter
11,000US$25.3k0%no data
0.063%
Albert Reese
10,917US$25.1k0%no data
0.063%
Al Rees
10,917US$25.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 00:19
End of Day Share Price 2025/01/03 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lexaria Bioscience Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ammar ShahEight Capital
Yi ChenH.C. Wainwright & Co.
Michael OkunewitchMaxim Group